Dr. Sarah Schaidle discusses factor XI inhibitors and the OCEANIC-AF trial with CardioScripts co-host Dr. Nathan Wayne.
0:00-0:59: Introduction
0:56-4:26: OCEANIC-AF trial overview
4:27-7:08: Overview of Factor XI (FXI) inhibition
7:09-08:29: New drug targets for FXI inhibition
08:30-11:17: OCEANIC-AF trial discussion
14:01-17:03 : Other areas of interest for FXI inhibitors
17:04-19:23: Ongoing phase 3 trials
19:25-20:10: Final thoughts
20:18-20:46: Closing
References:
OCEANIC-AF
Piccini, Jonathan P., et al. “Asundexian versus apixaban in patients with atrial fibrillation.” New England Journal of Medicine 392.1 (2025): 23-32.
PACIFIC-AF
Piccini, Jonathan P., et al. “Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study.” The Lancet 399.10333 (2022): 1383-1390.
FOXTROT
Weitz, Jeffrey I., et al. “Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT randomized clinical trial.” Jama 323.2 (2020): 130-139.
AXIOMATIC
Sharma, Mukul, et al. “Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial.” The Lancet Neurology 23.1 (2024): 46-59.
PACIFIC-AMI
Rao, Sunil V., et al. “A multicenter, phase 2, randomized, placebo-controlled, double-blind, parallel-group, dose-finding trial of the oral factor XIa inhibitor asundexian to prevent adverse cardiovascular outcomes after acute myocardial infarction.” Circulation 146.16 (2022): 1196-1206.
CardioScripts 